Awaiting development: Guidance and quality standards
Showing 351 to 355 of 355
| Title | Type |
|---|---|
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477] | Technology appraisal guidance |
| Zavegepant for treating acute migraine [TSID11998] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |
| Zongertinib for untreated HER2-positive unresectable advanced non-small-cell lung cancer [ID6573] | Technology appraisal guidance |